Tests give Fluad the all clear, says Italian agency
This article was originally published in Scrip
Executive Summary
Results of initial tests carried out on the two batches of Novartis' flu vaccine Fluad that were suspended in Italy on 27 November as a result of reports of serious adverse events, including deaths, are "completely negative" and show there is nothing wrong with the quality of the products, says the regulatory agency AIFA.